The case in front of me: six weeks · oral semaglutide.
The claim is plausible, which is exactly why I want to check it.
I am able to read a paper if someone points me at one.
Can anyone point me at a primary source, or confirm that there is not one?
In practice, the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Worth being precise here: the published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
The top of the schedule is not the target. The working dose is.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThis is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Stepping back is a normal adjustment, not a failure.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Specifically, titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Hold rather than escalate while symptoms are active. Always.
The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Slower costs time and nothing else. The ceiling is the same.
edited 5 Nov 2024 by Dr_Nadia_Farsi — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.